https://www.selleckchem.com/pr....oducts/gsk2578215a.h
001) and faecal calprotectin from 776 to 305 μg/g (P 0.001). Ustekinumab treatment in patients with highly refractory Crohn's disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity. Ustekinumab treatment in patients with highly refractory Crohn's disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity.L
Gefällt mir
Kommentar
Teilen
